Since most BC patients are not currently tested in the clinical practice for BRCA1/2 mutations, we assessed the clinical utility of PredictCBC version 1B to provide individualized CBC risk estimates for first BC patients not tested for BRCA1/2 germline mutations [60, 71]. This evidence concerns the gene BRCA1 and breast cancer.